Royce & Associates LP Viking Therapeutics, Inc. Transaction History
Royce & Associates LP
- $10.3 Billion
- Q4 2024
A detailed history of Royce & Associates LP transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Royce & Associates LP holds 75,261 shares of VKTX stock, worth $2.26 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
75,261
Previous 13,334
464.43%
Holding current value
$2.26 Million
Previous $844,000
258.77%
% of portfolio
0.03%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding VKTX
# of Institutions
468Shares Held
65.8MCall Options Held
5.84MPut Options Held
3.76M-
Vanguard Group Inc Valley Forge, PA10.2MShares$306 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$181 Million0.01% of portfolio
-
State Street Corp Boston, MA4.93MShares$148 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.59MShares$78 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.16MShares$64.9 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.31B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...